How Will Shire (SHPG) Stock Respond To Expected Merger With AbbVie (ABBV)?

NEW YORK (TheStreet) -- Shares of Shire  (SHPG) are up 1.50% to $253. on heavy trading volume after it was reported that the Dublin-based drugmaker and Chicago-based AbbVie (ABBV) plan to announce a $53 billion merger as soon as tomorrow, sources told Reuters.

Earlier this week, Shire said it was ready to recommend a deal to shareholders after AbbVie upped its offer.

Under British takeover rules, AbbVie has until July 18 to announce a firm offer for Shire, extend the deadline for an offer, or walk away, Reuters noted.

 
Shares of AbbVie are up 1.40% to $54.40, also on heavy trading volume.
 

TheStreet Ratings team rates SHIRE PLC as a Buy with a ratings score of A+. TheStreet Ratings Team has this to say about their recommendation:

"We rate SHIRE PLC (SHPG) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, notable return on equity, compelling growth in net income and good cash flow from operations. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value."

If you liked this article you might like

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Biotech Movers: Red Hill Jumps After Securing Rights Sell GERD Treatment

Shire Gains as it Seeks European Approval For Dry Eye Treatment

Tesla and Apple Better Deliver Big-Time or Look Out Below -- Week Ahead